View Filing Data

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2014	Apr. 28, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	HERON THERAPEUTICS, INC. /DE/
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		23,901,497
Amendment Flag	false
Entity Central Index Key	0000818033
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Mar. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1

Condensed Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2014	Dec. 31, 2013
Current assets:
Cash	$ 57,475	$ 72,287
Prepaid expenses and other current assets	2,262	638
Total current assets	59,737	72,925
Property and equipment, net	2,926	2,882
Other long-term assets	130	130
Total assets	62,793	75,937
Current liabilities:
Accounts payable	3,603	1,264
Accrued expenses	2,617	4,703
Convertible notes payable to related parties, net of discount	1,164	1,025
Total current liabilities	7,384	6,992
Stockholders’ equity:
Common stock	239	237
Additional paid-in capital	311,578	307,578
Accumulated deficit	(256,408)	(238,870)
Total stockholders’ equity	55,409	68,945
Total liabilities and stockholders’ equity	$ 62,793	$ 75,937

Condensed Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Operating expenses:
Research and development	$ 11,771	$ 7,140
General and administrative	5,551	5,612
Total operating expenses	17,322	12,752
Loss from operations	(17,322)	(12,752)
Interest expense	(216)	(201)
Net loss	$ (17,538)	$ (12,953)
Basic and diluted net loss per share (in Dollars per share)	$ (0.74)	$ (0.85)
Shares used in computing basic and diluted net loss per share (in Shares)	23,686	15,254

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Operating activities:
Net loss	$ (17,538,000)	$ (12,953,000)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization	114,000	70,000
Stock-based compensation expense	2,969,000	1,835,000
Amortization of debt discount	139,000	130,000
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(1,624,000)	157,000
Accounts payable	2,238,000	1,330,000
Accrued expenses	(2,011,000)	1,470,000
Net cash used for operating activities	(15,713,000)	(7,961,000)
Investing activities:
Purchases of property and equipment	(57,000)	(435,000)
Net cash used for investing activities	(57,000)	(435,000)
Financing activities:
Proceeds from warrant exercises		600,000
Proceeds from stock option exercises	958,000	12,000
Net cash provided by financing activities	958,000	612,000
Net decrease in cash	(14,812,000)	(7,784,000)
Cash at beginning of period	72,287,000	53,506,000
Cash at end of period	$ 57,475,000	$ 45,722,000

Note 1 - Business

3 Months Ended

Mar. 31, 2014

Disclosure Text Block [Abstract]

Business Description and Basis of Presentation [Text Block]

1. Business

Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.) (the “Company,” “we,” “us” and “our”) is a specialty pharmaceutical company developing product candidates using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.

Our lead product candidate, SUSTOL^TM (formerly known as APF530), is being developed for the prevention of acute chemotherapy-induced nausea and vomiting (“CINV”) for patients undergoing both moderately or highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuation of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. SUSTOL contains the 5-HT3 antagonist granisetron formulated in our proprietary Biochronomer polymer-based drug delivery platform, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. This five-day range is designed to cover the delayed phase of CINV. Granisetron was selected for SUSTOL because it is widely prescribed by physicians based on a well-established record of safety and efficacy.

In May 2009, we filed the original New Drug Application (“NDA”) seeking approval for SUSTOL with the U.S. Food and Drug Administration (“FDA”). The FDA issued a Complete Response Letter for the SUSTOL NDA in March 2010. In September 2012, we resubmitted our NDA for SUSTOL and, in March 2013, we received a second Complete Response Letter, which identified several remaining issues that need to be addressed prior to approval of the SUSTOL NDA. We are currently working on addressing these issues and expect to resubmit the SUSTOL NDA in mid-2014.

We own the worldwide rights to SUSTOL and are in the early stages of building the commercial infrastructure necessary to commercialize SUSTOL in the U.S. on our own, assuming approval by the FDA.

In addition, to resubmitting the SUSTOL NDA, we are seeking to expand the labeled indication for SUSTOL following its potential approval. In 2014, we initiated a Phase 3 clinical study with SUSTOL for the prevention of delayed CINV in patients receiving highly emetogenic chemotherapy, an indication for which no 5-HT3 antagonist is approved. The 1,000 patient study is expected to be completed in late 2014.

Our core Biochronomer technology, on which SUSTOL and our other product candidates are based, consists of bioerodible polymers designed to release drugs over a defined period of time. We have completed over 100 in vivo and in vitro studies demonstrating that our Biochronomer technology is potentially applicable to a range of therapeutic areas, including, among others, prevention of CINV, pain management and control of inflammation. We have also completed comprehensive animal and human toxicology studies that have established that our Biochronomer polymers are safe and well tolerated. Furthermore, our Biochronomer technology can be designed to deliver drugs over periods varying from days to potentially multiple weeks. We are exploring the potential use of our Biochronomer polymer with other drugs and intend to pursue the clinical development of one or more other drug candidates based on our proprietary delivery platform.

In November 2013, we initiated a program to expand our pipeline of sustained-release products, including a new program targeting the relief of post-surgical pain. Preliminary animal studies indicate that formulations using our Biochronomer polymer-based drug delivery platform provided sustained analgesic effects for three to five days. We plan to formalize optimization in 2014 and initiate a Phase 1 study in mid-2014. As of 2012, approximately 25 million¹ procedures associated with post-operative pain were conducted in the U.S. In addition, post-operative pain market sales were approximately $3.1 billion² in 2012.

In January 2014, we changed our name from A.P. Pharma, Inc. to Heron Therapeutics, Inc. Effective January 13, 2014, we effected a 1-for-20 reverse split of our outstanding common stock (“Reverse Stock Split”) (See Note 5). All historical share and per share amounts have been adjusted to reflect the Reverse Stock Split. All stock options, convertible notes and warrants outstanding were appropriately adjusted to give effect to the Reverse Stock Split.

Liquidity

We have incurred significant operating losses and negative cash flows from operations and we have an accumulated deficit of $256.4 million as of March 31, 2014. During 2011, 2012 and 2013, we completed a total of four rounds of equity and/or debt financings, which provided us with cash of approximately $135.4 million, net of issuance costs, to fund operations (see Notes 4 and 5). As of March 31, 2014, we had cash on hand of $57.5 million.

We believe that our current working capital is sufficient to fund essential operations into 2015; provided, however, that if we pursue additional clinical studies prior to 2015 or begin preparations for potential commercialization of SUSTOL, we will need to raise additional capital. We may require additional capital to fund our development pipeline programs. If we are unable to obtain sufficient financing on acceptable terms or otherwise, we may be required to reduce or defer our activities.

Note 3 - Accounting Policies

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

3. Accounting Policies

Use of Estimates

The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis, including those related to clinical trial accruals, income taxes and stock-based compensation. We base our estimates on historical experience and on assumptions that it believes to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.

Cash and Cash Equivalents

We consider all highly liquid investments with a maturity from the date of purchase of less than three months to be cash equivalents. We had cash of $57.5 million and $72.3 million at March 31, 2014 and December 31, 2013, respectively. There were no cash equivalents as of both dates. Our bank accounts have been placed under a control agreement in accordance with the April 2011 convertible note financing (see Note 4).

Earnings Per Share

Basic earnings per share (“EPS”) is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of common share equivalents. Diluted EPS is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, warrants and common stock underlying convertible notes are considered to be common stock equivalents and are only included in the calculation of diluted EPS when their effect is dilutive.

Because we have incurred a net loss for both periods presented in the unaudited condensed statements of operations, outstanding stock options, warrants and common stock underlying convertible notes are not included in the computation of net loss per share because their effect would be anti-dilutive.

The following table includes the number of outstanding stock options, warrants and common stock underlying convertible notes not included in the computation for the three months ended March 31, 2014 and 2013 (in thousands):

	Three Months Ended March 31,
	2014		2013

Stock options outstanding		7,273		4,461
Warrants outstanding		3,825		4,052
Common stock underlying convertible notes outstanding		6,385		6,016

Comprehensive Income (Loss)

Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive net loss for both periods presented was comprised solely of its net loss and there were no other changes in equity from non-owner sources.

Recent Accounting Pronouncements

We do not expect that the adoption of any recently issued accounting pronouncements would have a significant impact on our results of operations, financial condition or cash flow.

Note 4 - Convertible Notes to Related Parties

3 Months Ended

Mar. 31, 2014

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

4. Convertible Notes to Related Parties

In April 2011, we entered into a Securities Purchase Agreement for a private placement of up to $4.5 million in Senior Secured Convertible Notes (“Notes”). We received a total of $4.3 million, net of issuance costs, from the issuance of these Notes.

The Notes are secured by substantially all of our assets, including placing our bank accounts under a control agreement. The Notes bear interest at 6% per annum, payable quarterly in cash or in additional principal amount of Notes, at the election of the purchasers. The Notes mature on May 2, 2021, however, the holders of the Notes may require prepayment of the Notes at any time, at each holder’s option.

The Notes are convertible into shares of our common stock at a rate of 1,250 shares for every $1,000 of principal and accrued interest due under the Notes. There is no right to convert the Notes to the extent that, after giving effect to such conversion, the holder would beneficially own in excess of 9.99% of our outstanding common stock. Each holder of the Notes can increase or decrease this beneficial ownership conversion limit by written notice to us, which will not be effective until 61 days after delivery of the notice.

As of March 31, 2014, we were in compliance with all debt-related covenants under the Notes. Upon the occurrence of an event of default under the Notes, the holders of the Notes have the right to require us to redeem all or a portion of their Notes.

We filed a registration statement with the SEC to register for resale 3.5 million shares (as adjusted for the Reverse Stock Split) underlying the Notes. The registration statement was declared effective on July 29, 2011. The Purchasers have agreed to waive their right to require us to maintain the effectiveness of the registration statement and to register the additional shares underlying the Notes until they provide notice otherwise.

The Notes contain an embedded conversion feature that was in-the-money on the issuance dates. Based on an effective fixed conversion rate of 1,250 shares for every $1,000 of principal and accrued interest due under the Notes, the total conversion benefit at issuance exceeded the loan proceeds. Therefore, a full debt discount was recorded in an amount equal to the face value of the Notes on the issuance dates and we began amortizing the resultant debt discount over the respective 10-year term of the Notes. During the three months ended March 31, 2014, accrued interest of approximately $75,000 was paid-in-kind and rolled into the Note principal balance, which resulted in an additional debt discount of approximately $75,000. For the three months ended March 31, 2014 and 2013, interest expense relating to the stated rate was approximately $77,000 and $71,000, respectively, and interest expense relating to the amortization of the debt discount was approximately $139,000 and $130,000, respectively.

As of March 31, 2014, the carrying value of the Notes was approximately $1,164,000, which is comprised of the $5,108,000 principal amount of the Notes outstanding, less debt discount of $3,944,000. If the $5.1 million principal amount of Notes is converted, we would issue 6.4 million shares of our common stock.

Note 5 - Stockholders' Equity

3 Months Ended

Mar. 31, 2014

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

5. Stockholders’ Equity

Amendments to Articles of Incorporation – Reverse Stock Split

Effective January 13, 2014, we amended our Certificate of Incorporation to change our name to Heron Therapeutics, Inc. and to effect a 1-for-20 reverse split of our outstanding common stock. The name change and Reverse Stock Split were approved by our stockholders on September 19, 2013. As a result of the Reverse Stock Split, the total authorized shares of common stock were reduced from 1,500,000,000 to 75,000,000 shares.

2011 Private Placement

In June 2011, we sold 8.0 million shares of our common stock for net proceeds of $22.8 million (net of approximately $1.2 million in issuance costs). For each share purchased, the investors received one warrant to purchase 0.5 shares of common stock at an exercise price of $3.60 per share. The warrants were immediately exercisable and expire on July 1, 2016. The warrants may be exercised for cash only, or, if a registration statement is not then effective and available for the resale of the shares of common stock issuable upon exercise of the warrants, by surrender of such warrant, or a portion of such warrant, by way of cashless exercise. There is no right to exercise the warrants to the extent that, after giving effect to such exercise the holder would beneficially own in excess of 9.99% of our outstanding shares of common stock or such other limit as may be designated by any particular purchaser. Each holder of the warrants can amend or waive the foregoing limitation by written notice to us, with such waiver taking effect only upon the expiration of a 61-day notice period.

On July 29, 2011, we filed a registration statement with the SEC to register for resale the shares and the shares of common stock issuable upon the exercise of the warrants. The registration statement was declared effective on August 4, 2011. We are obligated to maintain the effectiveness of the registration statement until the investors are able to sell shares and the shares of common stock underlying the warrants without limitation or restriction under Rule 144 of the Securities Act of 1933, as amended (“Rule 144”). There is currently only one investor who is an affiliate of ours and is therefore not able to sell without limitation under Rule 144, and that investor has agreed to waive its right to require us to maintain the effectiveness of the registration statement until it provides notice otherwise. If we fail to keep the registration statement continuously effective for a designated time (with limited exceptions) during the period we are obligated to maintain the registration statement, we may be obligated to pay to the investors liquidated damages in an amount equal to 1.0% per month of such investor’s pro rata interest in the total purchase price of the 2011 private placement, capped at a total penalty of 6.0%.

During the three months ended March 31, 2014, one warrant holder exercised 144,040 warrants under the cashless exercise provision in the warrant agreement, which resulted in the net issuance of 108,409 shares of common stock and no net cash proceeds to the Company. During the three months ended March 31, 2013, we received $0.6 million for cash exercises of these warrants.

2012 Private Placement

In July 2012, we sold 5.1 million shares of our common stock at a purchase price of $10.50 per share, resulting in net proceeds of approximately $50.5 million (net of approximately $3.1 million in issuance costs).

On August 24, 2012, we filed a registration statement with the SEC to register these shares for resale. The registration statement was declared effective on September 6, 2012. If we fail to keep the registration statement continuously effective for a designated time (with limited exceptions), we may be obligated to pay to each investor an amount equal to 1.5% per month of the aggregate purchase price of the unregistered shares held by such investor, capped at a total penalty of 9.0%.

2013 Common Stock Offering

In November 2013, we entered into an underwriting agreement, pursuant to which we sold a total of approximately 8.6 million shares of our common stock to the underwriters at a public offering price of $8.00 per share. We received total net proceeds of approximately $57.8 million (net of approximately $3.9 million in issuance costs).

The offering was made pursuant to the Company’s effective registration statement on Form S-3 (Registration No. 333-190550), which was previously filed with the SEC and was declared effective, and a prospectus supplement filed with the SEC. The offering was not registered under any state blue sky laws and was limited to “Qualified Institutional Buyers” (as defined in Rule 144A under the Securities Act of 1933, as amended) and certain other institutional and accredited investors, as permitted under applicable law. In the underwriting agreement, the Company agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute to payments that the underwriters may be required to make because of such liabilities.

Stock Option Exercises

For the three months ended March 31, 2014, approximately 215,000 shares of common stock were issued pursuant to the exercise of stock options, resulting in proceeds to the Company of approximately $958,000.

Stock-Based Compensation

The following table summarizes stock-based compensation expense for the three months ended March 31, 2014 and 2013 related to stock options and Employee Stock Purchase Plan (“ESPP”) purchase rights by expense category (in thousands):

	Three Months Ended March 31,
	2014		2013

Research and development	$	1,262	$	249
General and administrative		1,707		1,586
Stock-based compensation expense included in operating expenses	$	2,969	$	1,835

Impact on basic and diluted net loss per share	$	0.13	$	0.12

As of March 31, 2014, there was approximately $45.4 million of total unrecognized compensation cost related to non-vested, stock-based payment awards granted under all of the Company’s equity compensation plans. Total unrecognized compensation cost will be adjusted for future changes in estimated forfeitures. The Company expects to recognize this compensation cost over a period of 2.5 years, which is the weighted-average vesting period for all stock-based compensation awards.

The Company estimated the fair value of each option grant on the grant date using the Black-Scholes option valuation model with the following weighted-average assumptions:

Options:	March 31,
	2014			2013
Risk-free interest rate		2.0	%		1.1	%
Dividend yield		0.0	%		0.0	%
Volatility		153.0	%		152.4	%
Expected life (years)		6			6

The Company estimates the fair value of each purchase right granted under the ESPP at the beginning of each new offering period using the Black-Scholes option valuation model. A new offering period begins every six months in May and November of each year. For the three months ended March 31, 2014 and 2013, there were no new offering periods or ESPP purchase rights granted.

The following table summarizes the stock option activity for the three months ended March 31, 2014:

	Shares (in thousands)			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)
Balance at January 1, 2014		6,356		$	8.22		8.14
Granted		1,203		$	9.99
Exercised		(275	)	$	6.17
Expired and forfeited		(11	)	$	17.32
Balance at March 31, 2014		7,273		$	8.57		8.42

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Accounting Policies, by Policy (Policies)

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

Liquidity Disclosure [Policy Text Block]

We had cash of $57.5 million and $72.3 million at March 31, 2014 and December 31, 2013, respectively.

Earnings Per Share, Policy [Policy Text Block]

Earnings Per Share

	Three Months Ended March 31,
	2014		2013

Stock options outstanding		7,273		4,461
Warrants outstanding		3,825		4,052
Common stock underlying convertible notes outstanding		6,385		6,016

Comprehensive Income, Policy [Policy Text Block]

Comprehensive Income (Loss)

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

We do not expect that the adoption of any recently issued accounting pronouncements would have a significant impact on our results of operations, financial condition or cash flow.

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References + Details

Note 5 - Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2014

Stockholders' Equity Note [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

	Three Months Ended March 31,
	2014		2013

Research and development	$	1,262	$	249
General and administrative		1,707		1,586
Stock-based compensation expense included in operating expenses	$	2,969	$	1,835

Impact on basic and diluted net loss per share	$	0.13	$	0.12

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Options:	March 31,
	2014			2013
Risk-free interest rate		2.0	%		1.1	%
Dividend yield		0.0	%		0.0	%
Volatility		153.0	%		152.4	%
Expected life (years)		6			6

Schedule of Share-based Compensation, Activity [Table Text Block]

	Shares (in thousands)			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)
Balance at January 1, 2014		6,356		$	8.22		8.14
Granted		1,203		$	9.99
Exercised		(275	)	$	6.17
Expired and forfeited		(11	)	$	17.32
Balance at March 31, 2014		7,273		$	8.57		8.42

Note 1 - Business (Details) $ in Thousands		36 Months Ended
Note 1 - Business (Details) $ in Thousands	Jan. 13, 2014	Dec. 31, 2013 USD ($)	Mar. 31, 2014 USD ($)	Mar. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)
Common Stock [Member]
Note 1 - Business (Details) [Line Items]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20
Retained Earnings (Accumulated Deficit)		$ (238,870)	$ (256,408)
Proceeds from Issuance of Long-term Debt and Capital Securities, Net		135,400
Cash and Cash Equivalents, at Carrying Value		$ 72,287	$ 57,475	$ 45,722	$ 53,506

Note 4 - Convertible Notes to Related Parties (Details)		1 Months Ended		3 Months Ended
Note 4 - Convertible Notes to Related Parties (Details)	Jul. 29, 2011 shares	Jun. 30, 2011	Apr. 30, 2011 USD ($) shares	Mar. 31, 2014 USD ($)	Mar. 31, 2013 USD ($)	Dec. 31, 2013 USD ($)
Initial Closing Amount [Member]
Note 4 - Convertible Notes to Related Parties (Details) [Line Items]
Notes Authorized Under Private Placement Initial Closing			$ 4,300,000
Purchase Option [Member]
Note 4 - Convertible Notes to Related Parties (Details) [Line Items]
Purchase Option Under Private Placement			0.06
Notes Payable, Other Payables [Member] \| In Case of Debt Conversion [Member]
Note 4 - Convertible Notes to Related Parties (Details) [Line Items]
Debt Instrument, Face Amount				$ 5,100,000
Debt Instrument, Convertible, Number of Equity Instruments				6,400,000
Notes Payable, Other Payables [Member]
Note 4 - Convertible Notes to Related Parties (Details) [Line Items]
Convertible Debt Issuable In Connection With Private Placement1			$ 4,500,000
Debt Instrument, Maturity Date		May 02, 2021
Beneficial Ownership After Conversion		9.99%
Notice Period Associated with Beneficial Ownership Percentage Limitation, Convertible Notes		61 days
Paid-in-Kind Interest				$ 75,000
Debt Instrument, Unamortized Discount				3,944,000
Carrying Value of Notes Outstanding				1,164,000
Debt Instrument, Face Amount				5,108,000
Common Stock [Member]
Note 4 - Convertible Notes to Related Parties (Details) [Line Items]
Debt Instrument Conversion Ratio, Shares (in Shares) \| shares			1,250
Principal Amount [Member]
Note 4 - Convertible Notes to Related Parties (Details) [Line Items]
Debt Instrument Conversion Ratio, Multiple of Principal			$ 1,000
Common Shares Registered For Resale In Connection With Convertible Notes (in Shares) \| shares	3,500,000
Debt Instrument, Unamortized Discount				75,000
Interest Expense, Debt, Excluding Amortization				77,000	$ 71,000
Amortization of Debt Discount (Premium)				139,000	$ 130,000
Carrying Value of Notes Outstanding				$ 1,164,000		$ 1,025,000

Note 5 - Stockholders' Equity (Details)		1 Months Ended				3 Months Ended		15 Months Ended	28 Months Ended
Note 5 - Stockholders' Equity (Details)	Jan. 13, 2014 shares	Nov. 30, 2013 USD ($) $ / shares shares	Jul. 31, 2012 USD ($) $ / shares shares	Jul. 29, 2011	Jun. 30, 2011 USD ($) $ / shares shares	Mar. 31, 2014 USD ($) shares	Mar. 31, 2013 USD ($)	Sep. 30, 2013	Sep. 30, 2013
Scenario, Previously Reported [Member]
Note 5 - Stockholders' Equity (Details) [Line Items]
Common Stock, Shares Authorized \| shares	1,500,000,000
Common Stock [Member] \| Private Placement 2011 [Member]
Note 5 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues \| shares					8,000,000	108,409
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares					22,800,000
Payments of Stock Issuance Costs (in Dollars)					$ 1,200,000
Shares Available Per Warrant Exercised \| shares					0.5
Proceeds from Issuance of Common Stock (in Dollars)						$ 0
Common Stock [Member] \| Private Placement 2012 [Member]
Note 5 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues \| shares			5,100,000
Payments of Stock Issuance Costs (in Dollars)			$ 3,100,000
Stock Issued During Period, Value, New Issues (in Dollars)			$ 50,500,000
Common Stock [Member] \| Jefferies LLC [Member]
Note 5 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues \| shares		8,600,000
Payments of Stock Issuance Costs (in Dollars)		$ 3,900,000
Proceeds from Issuance of Common Stock (in Dollars)		$ 57,800,000
Sale of Stock, Price Per Share (in Dollars per share) \| $ / shares		$ 8.00
Common Stock [Member]
Note 5 - Stockholders' Equity (Details) [Line Items]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20
Warrant [Member] \| Private Placement 2011 [Member]
Note 5 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised \| shares						144,040
Private Placement 2011 [Member]
Note 5 - Stockholders' Equity (Details) [Line Items]
Exercise Price Arrangement, Warrants To Purchase Shares, Purchase Price Per Unit (in Dollars per Share) \| $ / shares					3.60
Limitation On Exercisable Warrants									9.99%
Effective Rate Of Liquidated Damages				1.00%
Private Placement Capped Penatly				6.00%
Proceeds from Warrant Exercises (in Dollars)							$ 600,000
Private Placement 2012 [Member]
Note 5 - Stockholders' Equity (Details) [Line Items]
Effective Rate Of Liquidated Damages								1.50%
Private Placement Capped Penatly								9.00%
Shares Issued, Price Per Share (in Dollars per share) \| $ / shares			$ 10.50
Common Stock, Shares Authorized \| shares	75,000,000
Proceeds from Warrant Exercises (in Dollars)							600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net \| shares						215,000
Proceeds from Stock Options Exercised (in Dollars)						$ 958,000	$ 12,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)						$ 45,400,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition						2 years 6 months

Note 5 - Stockholders' Equity (Details) - Option Valuation Assumptions	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Option Valuation Assumptions [Abstract]
Risk-free interest rate	2.00%	1.10%
Dividend yield	0.00%	0.00%
Volatility	153.00%	152.40%
Expected life (years)	6 years	6 years

Note 5 - Stockholders' Equity (Details) - Option Summary - $ / shares shares in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Option Summary [Abstract]
Shares		6,356
Weighted-Average Exercise Price		$ 8.22
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	8 years 153 days	8 years 51 days
Granted	$ 9.99
Granted	1,203
Exercised	(275)
Exercised	$ 6.17
Expired and forfeited	(11)
Expired and forfeited	$ 17.32
Shares	7,273
Weighted-Average Exercise Price	$ 8.57
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	8 years 153 days	8 years 51 days

Note 3 - Accounting Policies (Details) - Equity Excluded From Calculation of Diluted Earnings Per Share - shares shares in Thousands	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded	7,273	4,461
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded	3,825	4,052
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded	6,385	6,016

Note 5 - Stockholders' Equity (Details) - Stock-based Compensation Expense - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 1,262	$ 249
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	1,707	1,586
Share-based compensation expense	$ 2,969	$ 1,835
Impact on basic and diluted net loss per share (in Dollars per share)	$ 0.13	$ 0.12